Alexion Pharmaceuticals, Inc. (ALXN) Tops Q1 EPS by 27c

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q1 EPS of $1.53, $0.27 better than the analyst estimate of $1.26. Revenue for the quarter came in at $566.6 million versus the consensus estimate of $560.22 million.

Alexion Pharmaceuticals, Inc. sees FY2014 EPS of $4.75-$4.85, versus prior guidance of $4.37-$4.47 and the consensus of $4.49.

For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• UBS Downgrades Zhaojin Mining Industry Co Ltd (1818:HK) to Neutral
• JPMorgan Upgrades NAC Kazatomprom JSC (KAP:LI) to Overweight